Clinical insights on treatment sequencing and the role of talquetamab, highlighting its safety profile in patients with multiple myeloma.
Cemsidomide Combo May Produce Responses in Multiple Myeloma
Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma
Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population
Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.
Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM
Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.